{
    "clinical_study": {
        "@rank": "65526", 
        "arm_group": {
            "arm_group_label": "Part A - MTD", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Phase 1, multicenter, open-label, non-randomized, dose-escalation oncology study to evaluate\n      the administration of EC1456, BIW on Weeks 1 and 2 of a 4-week schedule (Part A), and to\n      assess preliminary efficacy results in focused patients with triple-negative breast cancer\n      (TNBC), advanced non-small cell lung cancer (NSCLC), ovarian cancer and hepatocellular\n      carcinoma (HCC) (10 patients each) treated at the MTD (Part B)."
        }, 
        "brief_title": "FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORS", 
        "condition": [
            "Solid Tumors", 
            "Triple-Negative Breast Cancer (TNBC)", 
            "Advanced Non-Small Cell Lung Cancer (NSCLC)", 
            "Ovarian Cancer", 
            "Hepatocellular Carcinoma (HCC)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Ovarian Neoplasms", 
                "Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients enrolled in Part A must receive the 99mTc- etarfolatide scan but they do not need\n        to have FR-positive target lesions.\n\n        Parts A and B:\n\n        To qualify for enrollment, the following criteria must be met:\n\n          -  Patients must have the ability to sign an approved informed consent form (ICF).\n\n          -  Patients must be \u2265 18 years of age.\n\n          -  Patients must have histology confirmed metastatic or locally advanced solid tumor\n             (preferably TNBC, NSCLC, ovarian, HCC) that has failed to respond to standard\n             therapy, is not a candidate for standard therapy, or for which standard therapy does\n             not exist.\n\n          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of\n             0 or 1.\n\n          -  Patients must have at least one measurable lesion per RECIST v1.1 criteria/Modified\n             RECIST for HCC.\n\n          -  For the purpose of obtaining a RECIST v1.1 baseline scan, patients must have a\n             radiological evaluation conducted no more than 28 days prior to beginning study\n             therapy. Note: For patients with a history of CNS metastasis, baseline radiological\n             imaging must include evaluation of the brain (MRI preferred or CT with contrast).\n\n          -  Patients must have recovered (to baseline/stabilization) from prior\n             cytotoxic-therapy-associated acute toxicities.\n\n          -  Patients with prior radiation therapy are eligible if they meet the following\n             criteria:\n\n               1. Previous radiation therapy is allowed to <25% of the bone marrow (Cristy and\n                  Eckerman, 1987).\n\n               2. Prior radiotherapy must be completed at least 2 weeks before patient begins\n                  study therapy.\n\n               3. Patient must have recovered from the acute toxic effects of the treatment before\n                  beginning study therapy.\n\n               4. Palliative for pain or symptom control must be completed at least one week\n                  before patient begins study therapy, and these lesions must be excluded as\n                  target and non-target lesions.\n\n          -  Patients must have adequate organ function:\n\n               1. Bone marrow reserve: Absolute neutrophil count (ANC) \u2265 1.5 x 109/L. Platelets \u2265\n                  100 x 109/L. Hemoglobin \u2265 9 g/dL.\n\n               2. Cardiac:\n\n          -  Left ventricular ejection fraction (LVEF) equal to or greater than the institutional\n             lower limit of normal.  LVEF must be evaluated within 28 days prior to C1D1.\n\n          -  Cardiac Troponin I and T within normal limit. c) Hepatic: Total bilirubin \u2264 1.5 x the\n             upper limit of normal (ULN). Alanine aminotransferase (ALT), aspartate\n             aminotransferase (AST) \u2264 3.0 x ULN OR \u2264 5.0 x ULN for patients with liver metastases.\n\n             d) Renal: Serum creatinine \u2264 1.5 x ULN, or for patients with serum creatinine > 1.5\n             ULN, creatinine clearance \u2265 50 mL/min.\n\n          -  Patients of childbearing potential:\n\n               1. All women of childbearing potential MUST have a negative serum pregnancy test\n                  within 1 week prior to the 99mTc-etarfolatide imaging procedure and within 1\n                  week prior to treatment with EC1456.\n\n               2. Women of child bearing potential must practice an effective method of birth\n                  control (e.g., oral, transdermal or injectable contraceptives, intrauterine\n                  device [IUD], or double-barrier contraception, such as diaphragm and spermicidal\n                  jelly) for the duration of their participation in the trial through 90 days\n                  following the last dose of EC1456.\n\n               3. Male patients who are sexually active must practice an effective method of birth\n                  control (e.g., condom and spermicidal jelly). Effective birth control methods\n                  should be used throughout study participation and for at least 90 days following\n                  the last dose of EC1456.\n\n        Part B Only:\n\n          -  All patients in Part B must have TNBC, NSCLC, ovarian cancer or HCC.\n\n          -  All patients in Part B must have all target lesions FR-positive by 99mTc-etarfolatide\n             scan.\n\n        All patients in Part B must fulfill all other initial inclusion criteria (except inclusion\n        criterion 3).\n\n        Exclusion Criteria:\n\n        Parts A and B:\n\n        The presence of any of the following will exclude patients from the study:\n\n          -  More than 4 prior cytotoxic/biologics regimens for metastatic disease.  Neoadjuvant\n             and adjuvant treatments would not count towards this criterion (Note: hormonal\n             therapy also would not count towards this criterion).\n\n          -  Chemotherapy, immunotherapy or biological therapy (including monoclonal antibodies)\n             within 28 days prior to EC1456 administration.\n\n          -  Known hypersensitivity to the components of the study therapy or its analogs.\n\n          -  Carcinomatous meningitis and/or symptomatic central nervous system (CNS) metastases.\n             Note: Asymptomatic patients with stable CNS metastatic lesions in CT or MRI scans in\n             the last 6 months are eligible.\n\n          -  Malignancies that are expected to alter life expectancy or may interfere with disease\n             assessment. Patients with adequately treated non-melanoma skin cancer, carcinoma in\n             situ of the cervix, or low-grade (Gleason score \u2264 6) localized prostate cancer,\n             ductal carcinoma in situ (DCIS) and patients with prior history of malignancy who\n             have been disease free for more than 3 years are eligible.\n\n          -  Serious cardiac illness or medical conditions such as unstable angina, pulmonary\n             embolism, or uncontrolled hypertension.\n\n          -  Anti-folate therapy such as methotrexate for rheumatoid arthritis.\n\n          -  Pregnant or lactating women.\n\n          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational\n             therapy.\n\n          -  Active infections (e.g., hepatitis or HIV carriers)\n\n        Part B Only:\n\n        All patients in Part B must have received no more than two prior chemotherapeutic\n        regimens.\n\n        All patients in Part B must fulfill all other initial exclusion criteria (except exclusion\n        criterion 1)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999738", 
            "org_study_id": "EC1456-01"
        }, 
        "intervention": {
            "arm_group_label": "Part A - MTD", 
            "intervention_name": "EC1456 and EC20", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Folic Acid", 
                "Vitamin B Complex"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "last_name": "Wael Harb, MD", 
                "phone": "765-446-5111"
            }, 
            "facility": {
                "address": {
                    "city": "Lafayette", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47905"
                }, 
                "name": "Horizon BioAdvance"
            }, 
            "investigator": {
                "last_name": "Wael Harb, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A PHASE 1 STUDY OF FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORS", 
        "overall_contact": {
            "email": "bnguyen@endocyte.com", 
            "last_name": "Binh Nguyen, MD", 
            "phone": "317-876-1713"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximum Tolerated Dose (MTD)", 
            "time_frame": "18-24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999738"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Endocyte", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Endocyte", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}